Alnylam Pharmaceuticals competitors
Alnylam Pharmaceuticals Competitors include Moderna Therapeutics, Immune Therapeutics, Celyad and Aerie Pharmaceuticals.
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. |  Moderna Therapeutics Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells. |  Immune Therapeutics Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing and distribution of immunotherapies. |  Celyad Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology. |  Aerie Pharmaceuticals Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. |
Founding Date | Founding Date 2002 | Founding Date N/A | Founding Date 2012 | Founding Date 2007 | Founding Date 2005 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Cambridge, US HQ Zug, CH Windsor And Maidenhead, GB | Locations Cambridge, US HQ Huddinge, SE Chicago, US Norwood, US Huntington, US Cambridge, US Cambridge, US | Locations Orlando, US HQ | Locations Mont-Saint-Guibert, BE HQ Boston, US | Locations Irvine, US HQ Dublin, IE Durham, US Bedminster Township, US |
Employees | Employees 514 | Employees 7213% increase | Employees 10 | Employees 801% increase | Employees 9536% increase |
Valuation ($) | Valuation ($) 7.9 b | Valuation ($) N/A | Valuation ($) 4.4 m | Valuation ($) 205.7 b | Valuation ($) 1.9 b |
Twitter followers | Twitter followers 8 k | Twitter followers 2.4 k | Twitter followers 94 | Twitter followers 1.6 k | Twitter followers N/A |
Financial ⚠ | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $205.8m (FY, 2017) | Revenue (est.) N/A | Revenue (est.) €3.5m (FY, 2017) | Revenue (est.) N/A |
Net income | Net income ($490.9m) (FY, 2017) | Net income ($255.9m) (FY, 2017) | Net income ($7.9m) (FY, 2017) | Net income (€56.4m) (FY, 2017) | Net income ($145.1m) (FY, 2017) |
Funding | |||||
Total funding raised | Total funding raised $ 710m | Total funding raised $ 1.7b | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 388.6m |
For sources of this data, please see the company profileDownload Excel
View company profiles
Moderna Therapeutics
HQ
Cambridge, US
Employees
721↑ 3% increase
Moderna Therapeutics develops messenger RNA therapeutics that produces human proteins for antibodies inside patient cells.
View companyImmune Therapeutics
HQ
Orlando, US
Employees
10
Immune Therapeutics is a specialty pharmaceutical company involved in the manufacturing and distribution of immunotherapies.
View companyCelyad
HQ
Mont-Saint-Guibert, BE
Employees
80↑ 1% increase
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
View companyAerie Pharmaceuticals
HQ
Irvine, US
Employees
95↑ 36% increase
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
View company